← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Bortezomib

FDA approved · Rx

Proteasome inhibitor

Also known as: Velcade, PS-341, LDP-341, LDP 341, Bortezomib accord, bortezomibum, Bortexomib

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 1106 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Bortezomib, known by the brand name Velcade, is a small dipeptide boronic acid compound that blocks the proteasome, the cellular machinery that breaks down unneeded proteins. By inhibiting it, bortezomib causes damaged and regulatory proteins to build up in cells, which is thought to push cancer cells, especially myeloma cells, toward cell death.

What the evidence shows

Automatic summaryHuman trials

Bortezomib is FDA approved for the treatment of multiple myeloma and mantle cell lymphoma, backed by more than 1,100 registered human trials reaching Phase 4 and over 12,000 published papers. Its use in other conditions remains investigational.

Key facts

Molecular formula
C19H25BN4O4
Molecular weight
384.2 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

1,106registered studies
Phase 4most advanced phase
51completed (sample)
12recruiting (sample)

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Phase 3Active Not RecruitingNCT00734877

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Phase 2TerminatedNCT01315873

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Phase 2CompletedNCT02441686

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Phase 2RecruitingNCT06083922

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

12,125papers referencing Bortezomib

pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels.

PLoS One2014

A phase 2 study of bortezomib in relapsed, refractory myeloma.

N Engl J Med2003

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

N Engl J Med2005

Improved survival in multiple myeloma and the impact of novel therapies.

Blood2008

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.